Insulin therapy becomes essential for many people with Type 2 diabetes. After starting insulin, people with diabetes that is poorly controlled with oral agents typically report improved well-being and treatment satisfaction. However, healthcare professionals and people with Type 2 diabetes are often reluctant to begin insulin treatment, citing such concerns as time/resources needed to educate patients, increased risks of hypoglycaemia and fear of injections, which lead them to focus on intensifying conventional oral therapy. Insulin glargine, which offers people with diabetes a once-a-day injection regimen with low risk of hypoglycaemia, is more likely to overcome such initial barriers than other more complex insulin regimens. Once-daily in...
Initiating insulin therapy with a basal insulin analogue has become a standard of care in the treatm...
BACKGROUND: Adding insulin to oral therapy in type 2 diabetes mellitus is customary when glycemic co...
Patients with type 2 diabetes (T2DM) on insulin therapy are less satisfied with their diabetes treat...
Insulin therapy becomes essential for many people with type 2 diabetes. After starting insulin, peop...
PRINCIPLES: We aimed to evaluate the efficacy of, and treatment satisfaction with, insulin glargine ...
Background: Few studies evaluate patients' perspectives when a new drug is introduced to treat chron...
BACKGROUND: Strict glycaemic control in type 2 diabetic patients is recommended in a number of treat...
Diabetes is a lifelong course disease, so insulin treatment has to be effective and safe, and patien...
Objective To evaluate the effects of insulin 30/70 twice daily or bedtime isophane (NPH) insulin plu...
Objective To evaluate the effects of insulin 30/70 twice daily or bedtime isophane (NPH) insulin plu...
OBJECTIVE: To determine the functional health status and treatment satisfaction in patients with ty...
Insulin glargine (LANTUS®) is a long-acting basal insulin analog. The aim of this observational stud...
none6BACKGROUND AND AIMS: Glargine improves glucose control and reduces the risk of nocturnal hypogl...
OBJECTIVE To determine the functional health status and treatment satisfaction in patients with type...
Anthony H BarnettBirmingham Heartlands Hospital, Birmingham, West Midlands, England, UKAbstract: Ins...
Initiating insulin therapy with a basal insulin analogue has become a standard of care in the treatm...
BACKGROUND: Adding insulin to oral therapy in type 2 diabetes mellitus is customary when glycemic co...
Patients with type 2 diabetes (T2DM) on insulin therapy are less satisfied with their diabetes treat...
Insulin therapy becomes essential for many people with type 2 diabetes. After starting insulin, peop...
PRINCIPLES: We aimed to evaluate the efficacy of, and treatment satisfaction with, insulin glargine ...
Background: Few studies evaluate patients' perspectives when a new drug is introduced to treat chron...
BACKGROUND: Strict glycaemic control in type 2 diabetic patients is recommended in a number of treat...
Diabetes is a lifelong course disease, so insulin treatment has to be effective and safe, and patien...
Objective To evaluate the effects of insulin 30/70 twice daily or bedtime isophane (NPH) insulin plu...
Objective To evaluate the effects of insulin 30/70 twice daily or bedtime isophane (NPH) insulin plu...
OBJECTIVE: To determine the functional health status and treatment satisfaction in patients with ty...
Insulin glargine (LANTUS®) is a long-acting basal insulin analog. The aim of this observational stud...
none6BACKGROUND AND AIMS: Glargine improves glucose control and reduces the risk of nocturnal hypogl...
OBJECTIVE To determine the functional health status and treatment satisfaction in patients with type...
Anthony H BarnettBirmingham Heartlands Hospital, Birmingham, West Midlands, England, UKAbstract: Ins...
Initiating insulin therapy with a basal insulin analogue has become a standard of care in the treatm...
BACKGROUND: Adding insulin to oral therapy in type 2 diabetes mellitus is customary when glycemic co...
Patients with type 2 diabetes (T2DM) on insulin therapy are less satisfied with their diabetes treat...